by jtcir-auto | Jan 5, 2021 | Press Releases
CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr....
by jtcir-auto | Dec 7, 2020 | Press Releases
CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
by jtcir-auto | Dec 7, 2020 | Press Releases
CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
by jtcir-auto | Nov 16, 2020 | Press Releases
– Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for...
by jtcir-auto | Nov 16, 2020 | Press Releases
– Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for...
by jtcir-auto | Nov 6, 2020 | Press Releases
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021- Continue to advance discussions to secure a commercialization partner for macimorelin in Europe and other key global markets- Ongoing evaluations...